Source:http://linkedlifedata.com/resource/pubmed/id/10215288
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
1999-5-17
|
pubmed:abstractText |
Transcoronary alcohol ablation (TAA) therapy of septal hypertrophy was recently proposed as a therapeutic modality for obstructive hypertrophic cardiomyopathy (HC). However, questions remain about the effect of TAA on exercise performance. We performed a time-course analysis of exercise capacity and exercise hemodynamics in 20 patients with symptomatic obstructive HC after TAA. Symptom-limited bicycle exercise testing was performed before and 3 and 12 months after TAA, and cardiac catheterization at 3-month follow-up. The pressure gradient of the left ventricular outflow tract immediately decreased from 58 +/- 8 to 4 +/- 1 mm Hg at rest (p <0.01) and from 143 +/- 11 to 30 +/- 6 mm Hg after extrasystole (p <0.01), but partially recovered at 3-month follow-up (14 +/- 4 and 40 +/- 9 mm Hg, respectively). Left ventricular end-diastolic pressure was not changed after TAA. Peak oxygen consumption increased from 19 +/- 2 to 23 +/- 1 ml/kg/min (p < 0.01) and exercise duration from 573 +/- 47 to 742 +/- 46 seconds (p <0.01) at 3-month follow-up, but thereafter reached a plateau. Abnormal patterns of exercise blood pressure response were shown in 9 patients but normalized after TAA. Major complications occurred in 4 patients: no reflow to the left anterior descending coronary artery in 2 patients and ventricular tachycardia requiring cardioversion in 2 patients. During the follow-up period, all patients survived with symptomatic improvement in 17 patients. Thus, TAA is a promising therapeutic modality with improvement in exercise capacity and abnormal exercise blood pressure response in obstructive HC. However, potential serious complications should be considered in the application of TAA.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0002-9149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
83
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1220-3
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10215288-Adult,
pubmed-meshheading:10215288-Blood Pressure,
pubmed-meshheading:10215288-Cardiomyopathy, Hypertrophic,
pubmed-meshheading:10215288-Echocardiography,
pubmed-meshheading:10215288-Embolization, Therapeutic,
pubmed-meshheading:10215288-Ethanol,
pubmed-meshheading:10215288-Exercise Tolerance,
pubmed-meshheading:10215288-Female,
pubmed-meshheading:10215288-Follow-Up Studies,
pubmed-meshheading:10215288-Heart Catheterization,
pubmed-meshheading:10215288-Heart Septum,
pubmed-meshheading:10215288-Humans,
pubmed-meshheading:10215288-Injections, Intra-Arterial,
pubmed-meshheading:10215288-Male,
pubmed-meshheading:10215288-Stroke Volume,
pubmed-meshheading:10215288-Treatment Outcome
|
pubmed:year |
1999
|
pubmed:articleTitle |
Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy.
|
pubmed:affiliation |
Department of Medicine, University of Ulsan, and the Sports Medicine Center, Asan Medical Center, Seoul, Korea.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|